TY - JOUR
T1 - Elevated pre-treatment IL-18 level is associated with HBeAg seroconversion in HIV–HBV coinfection
AU - Li, Yijia
AU - Xie, Jing
AU - Wang, Huanling
AU - Han, Yang
AU - Wang, Nidan
AU - Thio, Chloe L.
AU - Li, Taisheng
N1 - Funding Information:
This work was supported by National Natural Science Foundation of China (grant number 81361120391); National Institutes of Health (grant number R01AI106586); National Key Technologies R&D Program for the 12th Five-year Plan (grant number 2012ZX10001003-001); the 12th Five-Year Major New Drug Discovery Science and Technology (grant number 2012ZX09303013). JX was supported by the Johns Hopkins University Centre for AIDS Research (JHU CFAR) NIH/NIAID fund (grant number 1P30AI094189-01A1). The funders had no role in study design, data collection, data analyses, preparation of the manuscript or decision to publish. CLT reports receiving a research grant from Gilead Sciences. The remaining authors have no conflicts of interest.
Funding Information:
This work was supported by National Natural Science Foundation of China (grant number 81361120391); National Institutes of Health (grant number R01AI106586); National Key Technologies R&D Program for the 12th Five-year Plan (grant number 2012ZX10001003-001); the 12th Five-Year Major New Drug Discovery Science and Technology (grant number 2012ZX09303013). JX was supported by the Johns Hopkins University Centre for AIDS Research (JHU CFAR) NIH/NIAID fund (grant number 1P30AI094189-01A1). The funders had no role in study design, data collection, data analyses, preparation of the manuscript or decision to publish. CLT reports receiving a research grant from Gilead Sciences.The remaining authors have no conflicts of interest.
Publisher Copyright:
© 2017 International Medical Press.
PY - 2017
Y1 - 2017
N2 - Background: In HBV-infected patients, hepatitis B e antigen (HBeAg) seroconversion is associated with better outcomes. Interleukin-18 (IL-18) controls hepatitis B replication in a mouse model. However, its role in treatment response in HIV–HBV-coinfected patients is unknown. Methods: We enrolled 35 treatment-naive, HBeAg-positive, HIV–HBV-coinfected patients. HBV DNA, HIV RNA, CD4+ T-cell count, HBV surface antigen (HBsAg) quantification (qHBsAg), HBeAg quantification (qHBeAg) and IL-18 levels were measured prior to, at 24 and 48 weeks of HBV-active combination antiretroviral therapy (cART). Multivariate Poisson regression models with robust standard errors were used to determine factors associated with HBeAg seroconversion. Results: Twenty-one patients received tenofovir (TDF) + lamivudine (3TC) based cART while 14 patients received 3TC-based cART. After 48 weeks of treatment, 10 patients experienced HBeAg seroconversion. Compared with non-seroconverters, seroconverters had higher median HIV RNA (5.22 versus 4.58 log copies/ ml; P=0.030), lower median qHBsAg (3.97 versus 4.76 log IU/ml; P=0.011), lower median qHBeAg (1.61 versus 3.01 log PEIU/ml; P=0.004) and marginally higher median IL-18 (2.70 versus 2.53 log pg/ml; P=0.068) prior to ART. In the multivariate regression, higher baseline IL-18 (adjusted relative risk [aRR] 2.99 per 1 log pg/ml increase; P=0.035), high HIV RNA (aRR 1.84 per 1 log copies/ml; P=0.029) and low qHBeAg (aRR 0.71 per 1 log PEIU/ml; P=0.029) were significantly associated with HBeAg seroconversion. Conclusions: In HIV–HBV-coinfected patients with HBeAg positivity, higher IL-18 levels, HIV RNA load, as well as low qHBeAg prior to cART were associated with HBeAg seroconversion.
AB - Background: In HBV-infected patients, hepatitis B e antigen (HBeAg) seroconversion is associated with better outcomes. Interleukin-18 (IL-18) controls hepatitis B replication in a mouse model. However, its role in treatment response in HIV–HBV-coinfected patients is unknown. Methods: We enrolled 35 treatment-naive, HBeAg-positive, HIV–HBV-coinfected patients. HBV DNA, HIV RNA, CD4+ T-cell count, HBV surface antigen (HBsAg) quantification (qHBsAg), HBeAg quantification (qHBeAg) and IL-18 levels were measured prior to, at 24 and 48 weeks of HBV-active combination antiretroviral therapy (cART). Multivariate Poisson regression models with robust standard errors were used to determine factors associated with HBeAg seroconversion. Results: Twenty-one patients received tenofovir (TDF) + lamivudine (3TC) based cART while 14 patients received 3TC-based cART. After 48 weeks of treatment, 10 patients experienced HBeAg seroconversion. Compared with non-seroconverters, seroconverters had higher median HIV RNA (5.22 versus 4.58 log copies/ ml; P=0.030), lower median qHBsAg (3.97 versus 4.76 log IU/ml; P=0.011), lower median qHBeAg (1.61 versus 3.01 log PEIU/ml; P=0.004) and marginally higher median IL-18 (2.70 versus 2.53 log pg/ml; P=0.068) prior to ART. In the multivariate regression, higher baseline IL-18 (adjusted relative risk [aRR] 2.99 per 1 log pg/ml increase; P=0.035), high HIV RNA (aRR 1.84 per 1 log copies/ml; P=0.029) and low qHBeAg (aRR 0.71 per 1 log PEIU/ml; P=0.029) were significantly associated with HBeAg seroconversion. Conclusions: In HIV–HBV-coinfected patients with HBeAg positivity, higher IL-18 levels, HIV RNA load, as well as low qHBeAg prior to cART were associated with HBeAg seroconversion.
UR - http://www.scopus.com/inward/record.url?scp=85037053499&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85037053499&partnerID=8YFLogxK
U2 - 10.3851/IMP3136
DO - 10.3851/IMP3136
M3 - Article
C2 - 28195558
AN - SCOPUS:85037053499
SN - 1359-6535
VL - 22
SP - 523
EP - 527
JO - Antiviral therapy
JF - Antiviral therapy
IS - 6
ER -